[ Cluster A · Hereditary Cancer ]
You just got the result everyone fears. Here is what it actually means, what NCCN guidelines say to do next — enhanced screening, ovarian surveillance, risk-reducing options, family testing — and why a positive result is the beginning of a plan, not a sentence.
A positive BRCA result means you inherited a pathogenic variant in BRCA1 or BRCA2 — genes whose job is to repair damaged DNA and suppress tumor growth. It is a risk finding, not a diagnosis. Most people with a BRCA variant never develop cancer, but the odds are high enough that guidelines from the NCCN (National Comprehensive Cancer Network) change how you should be screened — starting now.
Lifetime breast cancer risk rises to up to 72% (vs ~12% in the general population). Ovarian cancer risk rises to up to 44% (vs ~1.3%). Pancreatic and prostate risk are also elevated.
Elevated lifetime breast and ovarian risk, plus meaningful male risk: men with BRCA2 variants have up to a 7% lifetime breast cancer risk (vs 0.1%) and up to 27% prostate cancer risk by age 80.
A positive result does not mean you have cancer or will definitely get it. It means your surveillance plan should start earlier and run deeper than standard population screening.
NCCN guidelines turn a positive BRCA result into a concrete action plan. Your clinician will tailor specifics, but the framework looks like this:
Annual breast MRI plus mammogram (mammogram typically added by 30), alternating so you are imaged roughly every six months — far earlier and more intensive than standard screening, which starts at 40.
Transvaginal ultrasound and CA-125 blood testing at regular intervals. Ovarian screening is less sensitive than breast imaging, which is why guidelines also discuss risk-reducing surgery.
Chemoprevention (e.g., tamoxifen), risk-reducing mastectomy, and risk-reducing salpingo-oophorectomy — NCCN discusses ovary and tube removal between ages 35–40 for BRCA1 carriers once childbearing is complete. These are personal decisions made with your care team, not obligations.
Each first-degree relative — parents, siblings, children — has a 50% chance of carrying the same variant. Your result gives them the chance to test for a known family mutation, which is faster and cheaper than a full panel.
Every positive Gene Matrix result includes a session with a board-certified genetic counselor to walk through your report, NCCN options, and how to talk to relatives — before you ever see a specialist.
Your report is formatted for clinical use: ACMG-classified variants, CLIA-certified lab results, and guideline references your oncologist or breast center can act on directly.
“The first week after my result I barely slept. Every headline I read made the numbers feel like a countdown. Then I had my counseling session and everything reframed: I wasn’t sick — I was informed. I booked my first MRI, my sister got tested, and my daughter will test when she’s old enough. The fear didn’t disappear, but it had somewhere to go. I was doing something about it.”
Anxiety, guilt, and even relief are all normal reactions to a positive result. Counselors consistently report that patients feel more in control after a surveillance plan is in place. If the emotional weight feels heavy, tell your counselor — psychological support is part of the process, not an afterthought.
[ GeneCancer · 108 Genes ]
Whether you're supporting a relative or checking your own risk after a family diagnosis, the GeneCancer 108-gene panel covers BRCA1, BRCA2, Lynch syndrome genes, and more — at up to 99.9% analytical accuracy. $499 one-time, or included with all 10 other tests in the $89/month membership ($59/mo billed annually, $712/yr). 30-day money-back guarantee.
No. A positive result means you inherited a variant that raises your lifetime risk — up to 72% for breast cancer and up to 44% for ovarian cancer with BRCA1 — but most carriers never develop cancer. It is a signal to start enhanced surveillance, not a diagnosis.
NCCN guidelines call for annual breast MRI plus mammogram beginning at age 25 (mammogram typically added by 30), ovarian surveillance with transvaginal ultrasound and CA-125 from 30–35, and a discussion of risk-reducing options including chemoprevention and surgery. Your clinician personalizes the schedule.
Yes — this is called cascade testing. Each first-degree relative has a 50% chance of carrying the same variant. Testing for a known family variant is simpler and less expensive than a full panel, and it can change screening decisions for relatives who test positive — or provide genuine reassurance to those who test negative.
Usually. A documented pathogenic BRCA variant typically satisfies NCCN-based medical-necessity criteria, which is what insurers use to authorize breast MRI, specialist consultations, and risk-reducing procedures. Gene Matrix provides physician-ready reports designed to support exactly these authorizations.
A VUS means a change was found but current evidence cannot classify it as harmful or harmless. NCCN advises making decisions on family history, not on a VUS. Variants are reclassified over time — Gene Matrix membership includes quarterly AI reinterpretation, so you are notified if your VUS is ever resolved.
GeneCancer screens 108 genes including BRCA1 and BRCA2 from an at-home cheek swab, with results in 5–7 days (48-hour priority available) and a genetic counselor included with every positive result. No referral needed: $499 one-time or included with the $89/month membership.